Premium
Elevated AF1q expression is a poor prognostic marker for adult acute myeloid leukemia patients with normal cytogenetics
Author(s) -
Strunk Crawford J.,
Platzbecker Uwe,
Thiede Christian,
Schaich Markus,
Illmer Thomas,
Kang Zizhen,
Leahy Patrick,
Li Chunbiao,
Xie Xiuyan,
Laughlin Mary J.,
Lazarus Hillard M.,
Gerson Stanton L.,
Bunting Kevin D.,
Ehninger Gerhard,
Tse William
Publication year - 2009
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.21396
Subject(s) - medicine , myeloid leukemia , cytogenetics , oncology , hematology , chemotherapy , transplantation , leukemia , incidence (geometry) , gastroenterology , biochemistry , chemistry , physics , optics , chromosome , gene
Nearly half of the patients with newly diagnosed acute myeloid leukemia have normal cytogenetics (NC‐AML) and are classified as intermediate risk, but their 5‐year overall survival (OS) ranges from 24 to 42%. Therefore, molecular biomarkers to identify poor‐risk patients are needed. Elevated AF1q expression in the absence of specific poor cytogenetics is associated with poor outcomes in pediatric patients with AML and adult patients with myelodysplastic syndrome. We examined AF1q expression in 290 patients with NC‐AML. We found that patients with low AF1q ( n = 73) expression ( AF1q low ) have better OS ( P = 0.026), disease‐free survival ( P = 0.1), and complete remission rate ( P = 0.06) when compared with patients with high AF1q expression ( AF1q high n = 217). The patients with AF1q high had significantly greater incidence of concurrent tyrosine kinase3 internal tandem duplication. A subgroup of the patients with AF1q high who received allogeneic stem cell transplantation (SCT) had a significant better relapse‐free survival when compared with patients who received chemotherapy/autologous SCT ( P = 0.04). This study suggests that high AF1q expression is a poor prognostic marker for adult patients with NC‐AML.